Top

Published in:

01-08-2014 | Original Paper

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5

Authors: Jun Dong, Wang Li, Annan Dong, Siyue Mao, Lujun Shen, Sheng Li, Xiao Gong, Peihong Wu

Published in: Medical Oncology | Issue 8/2014

Abstract

The objective of this study was to assess the clinical efficacy of genetically engineered recombinant human adenovirus type 5 (rhAd5) plus transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (HCC). Data from two groups of patients with unresectable HCC were retrospectively reviewed. One group included 149 patients treated with rhAd5 injection, and the other included 150 control patients without gene therapy. Differences in short-term treatment effectiveness and adverse events were recorded and compared between the two groups. Our results indicated that for patients with higher tumor staging in the treatment group, the overall response rate and the disease control rate were higher than those in the control group, but not statistically significant (P > 0.05). The total progression free survival (PFS) and overall survival (OS) were significantly longer in the treatment group than the control group (240 vs. 196 days, P < 0.05; and 1,526 vs. 1,236 days, P = 0.000; respectively). The overall incidence rate of treatment-related adverse effects was similar (P > 0.05). No serious complications were observed. In conclusion, this study suggests that rhAd5 is a safe, effective gene therapy that prolongs the PFS and OS time of patients with unresectable HCC.

Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase [Internet]. 2014;11.

Tsuchiya M, Watanabe M, Koike J, Kubota Y, Suzuki T, Otsuka Y, et al. Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Gan to kagaku ryoho Cancer & chemotherapy. 2010;37(12):2594–7.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. doi:10.1016/j.jhep.2006.05.013.PubMedCrossRef

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134.PubMedCrossRef

Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–20. doi:10.1016/j.ctrv.2010.07.006.PubMedCrossRef

Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, et al. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer. 2006;118(8):2064–71. doi:10.1002/ijc.21585.PubMedCrossRef

Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37–51. doi:10.1111/j.1872-034X.2007.00216.x.PubMedCrossRef

Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):773–5.PubMedCentralPubMedCrossRef

Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4. doi:10.1245/s10434-010-1024-1.PubMedCrossRef

10.

Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res. 2013;19(6):1312–4. doi:10.1158/1078-0432.CCR-12-3796.PubMedCrossRef

11.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81. doi:10.1016/S1053-4296(03)00031-6.PubMedCrossRef

12.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

13.

Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 2013;36(5):287–93. doi:10.1097/CJI.0b013e3182948452.PubMedCrossRef

14.

Miller DL, Myers CL, Rickards B, Coller HA, Flint SJ. Adenovirus type 5 exerts genome-wide control over cellular programs governing proliferation, quiescence, and survival. Genome Biol. 2007;8(4):R58. doi:10.1186/gb-2007-8-4-r58.PubMedCentralPubMedCrossRef

15.

Min YW, Lee JH, Gwak GY, Paik YH, Lee JH, Rhee PL, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29(5):1043–8. doi:10.1111/jgh.12504.PubMedCrossRef

16.

Kocyigit A, Dicle O, Goktay Y, Astarcioglu I. The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. Diagn Interv Radiol. 2014;. doi:10.5152/dir.2014.13462.PubMed

17.

Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Cardiovasc Interven Radiol. 2012;35(1):82–9. doi:10.1007/s00270-010-0086-6.CrossRef

18.

Graham FL, van der Eb AJ, Heijneker HL. Size and location of the transforming region in human adenovirus type 5 DNA. Nature. 1974;251(5477):687–91.PubMedCrossRef

19.

Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene. 1998;16(3):349–57. doi:10.1038/sj.onc.1201540.PubMedCrossRef

20.

Iftode C, Flint SJ. Viral DNA synthesis-dependent titration of a cellular repressor activates transcription of the human adenovirus type 2 IVa2 gene. Proc Natl Acad Sci USA. 2004;101(51):17831–6. doi:10.1073/pnas.0407786101.PubMedCentralPubMedCrossRef

Title: Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5
Authors: Jun Dong
Wang Li
Annan Dong
Siyue Mao
Lujun Shen
Sheng Li
Xiao Gong
Peihong Wu
Publication date: 01-08-2014
Publisher: Springer US
Published in: Medical Oncology / Issue 8/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0095-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer

Combined detection of Gab1 and Gab2 expression predicts clinical outcome of patients with glioma

Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients

Serine–arginine protein kinase 1 is associated with breast cancer progression and poor patient survival

Combined effect of tobacco and DNA repair genes polymorphisms of XRCC1 and XRCC2 influence high risk of head and neck squamous cell carcinoma in northeast Indian population

Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page